Paliperidone Krka (Paliperidone)

Paliperidone works by blocking dopamine D2 receptors and serotonin 5‑HT2A receptors in the brain, which reduces excessive dopaminergic activity linked to psychosis. Its additional activity at α1‑adrenergic, histamine H1 and muscarinic receptors contributes to its overall antipsychotic profile and influences side‑effect patterns.

The appropriate dose of Paliperidone Krka is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage adjustments are made according to treatment guidelines and patient-specific factors; patients should follow the prescriber’s instructions precisely.

Paliperidone should only be used during pregnancy or lactation if the potential benefit justifies the potential risk to the fetus or infant. Limited data are available, so clinicians usually reserve its use for situations where alternative treatments are unsuitable, and they monitor both mother and child closely.

To order Paliperidone Krka, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Paliperidone is the primary active metabolite of risperidone and shares a similar receptor binding profile, but it offers a once‑daily oral formulation with a more predictable pharmacokinetic profile. Compared with older typical antipsychotics, it has a lower risk of extrapyramidal symptoms but may cause prolactin elevation and metabolic changes.

Paliperidone Krka tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keeping the product in a dry, well‑ventilated area helps maintain its stability throughout its shelf life.

Paliperidone Krka is supplied as an oral tablet that is taken whole with water, usually once daily. It can be taken with or without food, but patients should follow the prescriber’s guidance on timing relative to meals to ensure consistent absorption.

Serious risks include neuroleptic malignant syndrome, tardive dyskinesia, seizures, significant orthostatic hypotension, hyperglycaemia, and cardiac arrhythmias such as QT‑interval prolongation. Patients should be monitored regularly for these events, and any concerning symptoms require immediate medical evaluation.

Paliperidone is contraindicated in individuals with known hypersensitivity to paliperidone or any of its excipients, and it should be avoided in patients with severe uncontrolled cardiovascular disease, a history of neuroleptic malignant syndrome, or those who are currently taking strong CYP3A4 inhibitors without appropriate dose adjustment.